株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

臓器チップのイノベーションが創薬スクリーニング用途を後押し

Organ-On-A-Chip Innovations Fueling Drug Screening Applications

発行 Frost & Sullivan 商品コード 662141
出版日 ページ情報 英文 70 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.31円で換算しております。
臓器チップのイノベーションが創薬スクリーニング用途を後押し Organ-On-A-Chip Innovations Fueling Drug Screening Applications
出版日: 2018年06月29日 ページ情報: 英文 70 Pages
概要

新しい臓器チッププラットフォームは、製薬業界における創薬スクリーニングプロセスを変えてしまう可能性があります。

当レポートでは、臓器チップのイノベーションについて調査分析し、技術の概要、現状、促進要因と課題、主要企業、IP情勢、成長機会など、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 技術のスナップショット

  • 臓器チップ機能の概要
  • 創薬スクリーニングプロセスにおける臓器チップ技術の主要促進要因
  • 臓器チッププラットフォームにおける現在の動向

第3章 臓器チッププラットフォーム

  • 心臓チッププラットフォーム
  • 肝臓チッププラットフォーム
  • 肺チッププラットフォーム
  • 腎臓チッププラットフォーム
  • 腸チッププラットフォーム
  • 神経チッププラットフォーム
  • 筋肉チッププラットフォーム
  • 脳チッププラットフォーム
  • 多臓器チッププラットフォーム
  • ヒトチッププラットフォーム

第4章 臓器チップ技術の促進要因と課題

  • 臓器チップ技術に影響を与える促進要因と課題
  • 臓器チップ技術
  • 幹細胞

第5章 主要な臓器チップ企業

  • CN Bio
  • Emulate
  • Hesperos
  • ParVivo
  • TissUse、など

第6章 臓器チップ技術のIP情勢

  • 特許範囲と概念
  • 臓器チッププラットフォームの特許権者 (上位20)
  • 臓器チップ特許ポートフォリオの分布 (特許事務所別)
  • 臓器チップ特許ポートフォリオの特許公開分布 (年別)

第7章 臓器チップ技術の資金情勢

  • 臓器チップ技術の資金力:世界分析
  • 臓器チップ開発の政府資金
  • 臓器チップ市場におけるVCベースの投資資金
  • 臓器チップ技術開発の資金に関する動物実験無し研究

第8章 成長機会

  • 成長機会1
  • 成長機会2
  • 成長機会3
  • 創薬スクリーニングプロセスに対する臓器チッププラットフォームの影響の決定要因

第9章 付録

目次
Product Code: D84A

Novel Organ-chip Platforms Likely to Transform the Drug Screening Process in the Pharmaceutical Industry

Organ-on-a-chip technology involves the incorporation of microphysiological systems harboring dynamic living 3D organoids, tissue-culture, or cell cultures on a microfluidic platform. The physiologically relevant Organ-chip models offer a better and more precise insight to the possible in vivo effects of drugs in the human body. The flexibility of Organ-on-a-chip is such that the innovation is not just human relevant per se but can mimic a wide variety of human functions such as breathing, heart beats, peristalsis, menstruation, neuronal communication.

Animal models and in vitro assays have served as the gold standard for pre-clinical research and study for a long time now. But for all the benefits, animal models and in vitro assays have seen poor results in human translation and prediction due to unsatisfactory human relevance. Organ-on-a-chip innovations are currently making themselves relevant by offering better data for human translation and prediction through their high degree of human relevant systems.

US are currently the frontrunners in the Organ-on-a-chip technology followed closely by Netherlands, United Kingdom and Germany. The countries have been capitalized on the need for a better study model in drug screening application to pioneer the development of Organ-on-a-chip innovations which has seen relative success in the pharmaceutical industry as evidenced by the adoption of Organ-chip technology by major pharmaceutical companies such as Roche, AstraZeneca among many others.

Table of Contents

1.0. EXECUTIVE SUMMARY

  • 1.1. Research Scope - Application of Organ-on-a-chip Technology in Drug Screening Process
  • 1.2. Research Methodology - The Frost & Sullivan Core Value
  • 1.3. Key Findings: Organ-on-a-chip Technology

2.0. TECHNOLOGY SNAPSHOT

  • 2.1. A Brief Overview of Organ-on-a-chip Functioning
  • 2.2. Key Factors Empowering Organ-on-a-chip Technologies for Drug Screening Processes
  • 2.3. Current Trends in the Organ-on-a-chip platform

3.0. ORGAN-ON-A-CHIP PLATFORMS

  • 3.1. Heart-on-a-chip Platform
  • 3.2. Liver-on-a-chip Platform
    • 3.2.1. High Throughput Capability of Liver-on-a-chip Platforms Integral to Large-Scale Drug Screening Applications
    • 3.2.2. Flow Systems Adopted in Liver-on-a-chip Platforms that Facilitate Stability
  • 3.3. Lung-on-a-chip Platform
    • 3.3.1. Lung-on-a-chip: Platform Overview, Application, Disadvantages and Features
  • 3.4. Kidney-on-a-chip Platform
    • 3.4.1. Kidney-on-a-chip: Features, Platform Design, Applications, and Challenges
  • 3.5. Gut-on-a-chip/Intestine-on-a-chip Platform
    • 3.5.1. Intestine- and Gut-on-a-chip Serve as Enhanced Study Models
    • 3.5.2. Intestine- and Gut-on-a-chip: The Applications and the Challenges
  • 3.6. Nerve-on-a-chip Platform
    • 3.6.1. Evaluation of Neurotoxicity with Nerve-on-a-chip platform
  • 3.7. Muscle-on-a-chip Platform
    • 3.7.1. Muscle-on-Chip Platform to Determine Long-term rug ffects on Muscle Loss and Toxicity
    • 3.7.2. Muscle-on-a-chipPhysiology, Features and Application Areas
  • 3.8. Brain-on-a-chip Platform
    • 3.8.1. Emulation of Human-Blood-Brain Barrier
  • 3.9. Multi-Organ Chip Platforms
  • 3.10. Human-on-a-chip Platform

4.0. DRIVERS AND CHALLENGES OF ORGAN-CHIP TECHNOLOGY

  • 4.1. Drivers and Challenges Impact Chart of Organ-Chip Technology
  • 4.2. Organ-on-a-chip Technology
  • 4.3. Stem ell henotypes key to unlocking vast otential of Organ-chip Systems

5.0. MAJOR ORGAN-ON-A-CHIP COMPANIES

  • 5.1. A Well-defined and Robust Nerve-on-a-chip Platform
  • 5.2. CN Bio- UK's Organ-chip Technology Pioneer
  • 5.3. Emulate propelling Drug Screening and Development through their
  • 5.4. Hesperos facilitates superior Serum-free Media and Pumpless Organ-Chip Systems
  • 5.5. Liver-on-a-chip platforms with High Biological Fidelity
  • 5.6. Scaffold-free Human Relevant Liver-on-a-Chip Systems
  • 5.7. Validated Research-ready Organ-chip Systems
  • 5.8. Organ-Chips that facilitate High Throughput Screening
  • 5.9. Precise Flow-controlled ParVivo Organ-Chip Systems
  • 5.10. Replicating In Vivo Cardiac Biology on an n Vitro Chip Platform
  • 5.11. TissUse pioneering Human-on-a-Chip platform

6.0. INTELLECTUAL PROPERTY LANDSCAPE OF ORGAN-ON-A-CHIP TECHNOLOGY

  • 6.1. Patent Research Scope and Concepts
  • 6.2. Top 20 Patent Holders in the Organ-on-a-chip Platform
  • 6.3. Patent Office-wise Distribution of Organ-on-a-chip Patent Portfolio, 2008-2018*
  • 6.4. Year-wise Publication Distribution of Organ-on-a-chip Patent Portfolio, 2008-2017

7.0. FUNDING LANDSCAPE OF ORGAN-ON-A-CHIP TECHNOLOGY

  • 7.1. Funding Strength of Organ-Chip Technology- Global View
  • 7.2. Government Funding for Organ-on-a-chip Development
  • 7.3. Venture Capitalist-based Investment Funding in the OOC Market
  • 7.4.Animal Free Research involved in Funding of Organ-on-a-chip Technology Development

8.0. GROWTH OPPORTUNITIES

  • 8.1. Growth Opportunity 1: Personalized Medicine
  • 8.2. Growth Opportunity 2: Animal Model Replacement
  • 8.3. Growth Opportunity 3: Identification of Biomarkers
  • 8.4. Determinants of Organ-on-a-chip Platform's Impact on Drug Screening Process

9.0. APPENDIX

  • 9.1. Key Contacts
  • 9.1. Key Contacts (continued)
  • Legal Disclaimer